BioMerieux ends colon cancer work with ExonHit

in Gold Investing by admin — March 7, 2010 11:37 pm | no comments

PARIS, March 8 – French pharmaceutical groups BioMerieux and ExonHit said on Monday they were ending their collaboration on colon cancer, but would continue to work together on prostate cancer. BioMerieux said its operating income rose 9.5 percent BioMerieux ends colon cancer work with ExonHit

Continued here:
BioMerieux ends colon cancer work with ExonHit

Tags: collaboration ends-colon french laboration-on-colon monday operating-income paris said-its said-on-monday together-on-prostate work-together